Systematic Financial Management LP Acquires 92,336 Shares of Jazz Pharmaceuticals plc (NASDAQ:JAZZ)

Systematic Financial Management LP lifted its position in Jazz Pharmaceuticals plc (NASDAQ:JAZZ - Free Report) by 32.5% in the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 376,313 shares of the specialty pharmaceutical company's stock after buying an additional 92,336 shares during the period. Jazz Pharmaceuticals comprises 1.2% of Systematic Financial Management LP's holdings, making the stock its 13th largest position. Systematic Financial Management LP owned 0.62% of Jazz Pharmaceuticals worth $46,343,000 at the end of the most recent quarter.

Several other hedge funds have also added to or reduced their stakes in JAZZ. Bessemer Group Inc. raised its holdings in shares of Jazz Pharmaceuticals by 0.3% during the fourth quarter. Bessemer Group Inc. now owns 26,932 shares of the specialty pharmaceutical company's stock worth $3,317,000 after acquiring an additional 92 shares during the period. CIBC Asset Management Inc increased its holdings in Jazz Pharmaceuticals by 5.2% during the 4th quarter. CIBC Asset Management Inc now owns 1,972 shares of the specialty pharmaceutical company's stock worth $243,000 after purchasing an additional 97 shares in the last quarter. Synovus Financial Corp raised its stake in shares of Jazz Pharmaceuticals by 0.5% in the 4th quarter. Synovus Financial Corp now owns 19,206 shares of the specialty pharmaceutical company's stock valued at $2,365,000 after purchasing an additional 100 shares during the period. Quarry LP raised its stake in shares of Jazz Pharmaceuticals by 6.3% in the 4th quarter. Quarry LP now owns 1,700 shares of the specialty pharmaceutical company's stock valued at $209,000 after purchasing an additional 100 shares during the period. Finally, Quadrant Capital Group LLC lifted its holdings in shares of Jazz Pharmaceuticals by 97.1% in the fourth quarter. Quadrant Capital Group LLC now owns 205 shares of the specialty pharmaceutical company's stock valued at $25,000 after purchasing an additional 101 shares in the last quarter. Institutional investors and hedge funds own 89.14% of the company's stock.

Insider Transactions at Jazz Pharmaceuticals

In related news, Director Seamus Mulligan purchased 1,621 shares of the stock in a transaction on Monday, May 12th. The shares were purchased at an average cost of $103.00 per share, with a total value of $166,963.00. Following the acquisition, the director now directly owns 101,621 shares in the company, valued at $10,466,963. The trade was a 1.62% increase in their ownership of the stock. The acquisition was disclosed in a document filed with the SEC, which is accessible through this link. Also, CMO Robert Iannone sold 7,080 shares of the company's stock in a transaction that occurred on Friday, March 7th. The shares were sold at an average price of $138.60, for a total value of $981,288.00. Following the completion of the transaction, the chief marketing officer now directly owns 82,024 shares in the company, valued at $11,368,526.40. The trade was a 7.95% decrease in their position. The disclosure for this sale can be found here. In the last 90 days, insiders sold 28,236 shares of company stock worth $3,956,190. 4.20% of the stock is owned by insiders.

Jazz Pharmaceuticals Stock Performance

NASDAQ JAZZ traded up $1.24 during trading on Tuesday, reaching $111.02. 1,230,970 shares of the company's stock were exchanged, compared to its average volume of 849,129. The company has a debt-to-equity ratio of 1.46, a current ratio of 4.26 and a quick ratio of 3.74. The business has a 50 day moving average price of $114.74 and a 200-day moving average price of $122.01. The stock has a market capitalization of $6.84 billion, a P/E ratio of 15.64, a PEG ratio of 1.04 and a beta of 0.38. Jazz Pharmaceuticals plc has a fifty-two week low of $95.49 and a fifty-two week high of $148.06.

Jazz Pharmaceuticals (NASDAQ:JAZZ - Get Free Report) last issued its earnings results on Tuesday, May 6th. The specialty pharmaceutical company reported $1.68 EPS for the quarter, missing the consensus estimate of $4.65 by ($2.97). Jazz Pharmaceuticals had a return on equity of 29.30% and a net margin of 11.60%. The business had revenue of $897.84 million for the quarter, compared to the consensus estimate of $984.16 million. During the same quarter in the prior year, the firm posted $2.68 earnings per share. The business's revenue was down .5% compared to the same quarter last year. Sell-side analysts forecast that Jazz Pharmaceuticals plc will post 16.96 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

A number of research firms recently issued reports on JAZZ. Truist Financial increased their price objective on Jazz Pharmaceuticals from $220.00 to $230.00 and gave the stock a "buy" rating in a report on Thursday, March 6th. Robert W. Baird lowered their price objective on shares of Jazz Pharmaceuticals from $167.00 to $155.00 and set an "outperform" rating on the stock in a report on Wednesday, May 7th. Royal Bank of Canada cut their price objective on shares of Jazz Pharmaceuticals from $182.00 to $172.00 and set an "outperform" rating on the stock in a research report on Wednesday, May 7th. Wells Fargo & Company raised shares of Jazz Pharmaceuticals from an "equal weight" rating to an "overweight" rating and raised their target price for the company from $130.00 to $170.00 in a research report on Thursday, February 13th. Finally, StockNews.com cut shares of Jazz Pharmaceuticals from a "buy" rating to a "hold" rating in a research report on Thursday, May 15th. Two analysts have rated the stock with a hold rating and thirteen have issued a buy rating to the stock. Based on data from MarketBeat.com, the company currently has an average rating of "Moderate Buy" and an average price target of $182.79.

Jazz Pharmaceuticals Profile

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia.